- Home
- CDIO vs KLTO Comparison
CDIO vs KLTO Comparison
Compare CDIO & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- KLTO
- Stock Information
- Founded
- CDIO 2017
- KLTO 2019
- Country
- CDIO United States
- KLTO United States
- Employees
- CDIO N/A
- KLTO N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- KLTO
- Sector
- CDIO Health Care
- KLTO
- Exchange
- CDIO Nasdaq
- KLTO NYSE
- Market Cap
- CDIO 6.4M
- KLTO 5.9M
- IPO Year
- CDIO N/A
- KLTO N/A
- Fundamental
- Price
- CDIO $4.39
- KLTO $1.23
- Analyst Decision
- CDIO Buy
- KLTO
- Analyst Count
- CDIO 1
- KLTO 0
- Target Price
- CDIO $60.00
- KLTO N/A
- AVG Volume (30 Days)
- CDIO 41.0K
- KLTO 13.6M
- Earning Date
- CDIO 08-11-2025
- KLTO 08-15-2025
- Dividend Yield
- CDIO N/A
- KLTO N/A
- EPS Growth
- CDIO N/A
- KLTO N/A
- EPS
- CDIO N/A
- KLTO N/A
- Revenue
- CDIO $19,902.00
- KLTO N/A
- Revenue This Year
- CDIO $1,434.82
- KLTO N/A
- Revenue Next Year
- CDIO $4,661.91
- KLTO N/A
- P/E Ratio
- CDIO N/A
- KLTO N/A
- Revenue Growth
- CDIO N/A
- KLTO N/A
- 52 Week Low
- CDIO $3.22
- KLTO $0.11
- 52 Week High
- CDIO $53.10
- KLTO $3.91
- Technical
- Relative Strength Index (RSI)
- CDIO 50.34
- KLTO N/A
- Support Level
- CDIO $4.11
- KLTO N/A
- Resistance Level
- CDIO $4.73
- KLTO N/A
- Average True Range (ATR)
- CDIO 0.33
- KLTO 0.00
- MACD
- CDIO 0.10
- KLTO 0.00
- Stochastic Oscillator
- CDIO 65.03
- KLTO 0.00
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.